Stephens reissued their overweight rating on shares of CareDx (NASDAQ:CDNA – Free Report) in a report issued on Wednesday morning, Benzinga reports. They currently have a $15.00 target price on the stock.
CareDx Stock Performance
CDNA stock opened at $8.31 on Wednesday. The firm has a market cap of $430.28 million, a PE ratio of -2.35 and a beta of 1.42. The firm’s 50 day moving average price is $9.67 and its 200-day moving average price is $9.16. CareDx has a one year low of $4.80 and a one year high of $12.93.
CareDx (NASDAQ:CDNA – Get Free Report) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($2.21) EPS for the quarter, missing the consensus estimate of ($0.24) by ($1.97). The firm had revenue of $65.57 million for the quarter, compared to analysts’ expectations of $63.66 million. CareDx had a negative net margin of 67.88% and a negative return on equity of 51.40%. The firm’s quarterly revenue was down 20.4% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.34) EPS. Equities research analysts predict that CareDx will post -1.59 EPS for the current fiscal year.
Institutional Trading of CareDx
CareDx Company Profile
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
See Also
- Five stocks we like better than CareDx
- What is the Hang Seng index?
- Comprehensive Analysis of PayPal Stock
- What does consumer price index measure?
- Intuitive Surgical Stock Can Trend Much Higher This Year
- The 3 Best Blue-Chip Stocks to Buy Now
- Alibaba Stock Analysis: Insights, Trends, and Future Predictions
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.